Medical Complications in Hemodialysis Patients Requiring Vascular Access Radiology Procedures

Vascular access maintenance is crucial to providing adequate hemodialysis (HD) and hence preventing signs and symptoms of uremia. The best vascular assess is a permanent arteriovenous fistula (AVF) because it has the longest survival with the least number of complications. However, because of problems with AVF maturation, the majority of HD in the United States is provided via an arteriovenous graft (AVG) or tunneled cuffed central venous catheter. The most common access complications include infection and thrombosis. For these reasons, a patient is often referred to interventional radiology for a procedure such as a catheter placement, change, or a thrombectomy with angioplasty and/or stent placement. Commonly, a HD patient will present after missing a dialysis session. This might predispose the patient to further complications. This review is intended to provide insight into some of the common medical problems (infectious, hematologic, and cardiac) facing a HD patient as a consequence of uremia. Increased awareness to these medical issues provides guidance to prevent unnecessary complications in this difficult patient population.

Hemodialysis - vascular access - interventional radiology - bacteremia - coagulation

REFERENCES

• 1 , NKF-K/DOQI Clinical Practice Guidelines for Vascular Access Update 2000.  Am J Kidney Dis. 2001;  37 S137-S181
• 2 US Renal Data System. USRDS 2002 Annual Data Report .Bethesda, MD; The National Institute of Diabetes and Digestive Diseases 2002 Chapter 4
• 3 Vanholder R, Van Loo A, DeSmet R, Ringoir S. Host defenses and infection in dialysis patients. In: Nissenson AR, Fine RN, Gentile DE Clinical Dialysis, 3rd ed. Norwalk, CT; Appleton & Lange 1996: 450-482
• 4 Nissenson A R, Charytan C. Controversies in iron management.  Kidney Int. 2003;  64 S64-S71
• 5 Descamps-Latscha B, Herbelin A, Nyugen A, Zingraff J, Jungers P, Chatenoud L. Immune system dysregulation in uremia.  Semin Nephrol. 1994;  14 253-269
• 6 Mailloux L U, Belluci A G, Wilkes B M. Mortality in dialysis patients: analysis of the causes of death.  Am J Kidney Dis. 1991;  18 326-335
• 7 Poduval R D, Hammes M S. Tuberculosis screening in dialysis patients-is the tuberculin test effective?.  Clin Nephrol. 2003;  59 436-440
• 8 Cheesebrough J S, Finch R G, Burden R P. A prospective study of the mechanisms of infection associated with hemodialysis catheters.  J Infect Dis. 1986;  154 579-589
• 9 Sands T F. Bacteremia associated with tunneled, cuffed hemodialysis catheters.  Am J Kidney Dis. 1999;  34 1114-1124
• 10 Kovalik E, Raymond J, Albers F et al.. A clustering of epidural abscesses in chronic hemodialysis patients: risks of salvaging access catheters in cases of infection.  J Am Soc Nephrol. 1996;  7 2264-2267
• 11 Berns J S, Tokars J I. Preventing bacterial infections and antimicrobial resistance in dialysis patients.  Am J Kidney Dis. 2002;  40 886-898
• 12 Roth R R, James W D. Microbial ecology of the skin.  Annu Rev Microbiol. 1988;  42 41-64
• 13 Montecalvo M A, Shay D K, Patel P, Tasca L, Naloney S A, Jarvis W R. Bloodstream infections with vancomycin-resistant enterococci.  Arch Intern Med. 1996;  156 1458-1462
• 14 Marr K A, Sexton D J, Conlon P J, Corey G R, Schwab S J, Kirkland K B. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis.  Ann Intern Med. 1997;  127 275-280
• 15 Tanriover B, Carlton D, Saddekni S et al.. Bacteremia associated with tunneled catheters: comparison of two treatment strategies.  Kidney Int. 2000;  57 2151-2155
• 16 Robinson D, Suhocki P, Schwab S. Treatment of infected tunneled venous access hemodialysis catheters with guidewire exchange.  Kidney Int. 1998;  53 1792-1794
• 17 Hammes M S, Poduval R, Ferrell J. The effect of intensive hemodialysis (HD) on anergy in dialysis patients-results of a prospective study.  J Am Soc Nephrol. 2003;  14 212A
• 18 Yu V L, Goetz A, Wagener M. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis.  N Engl J Med. 1986;  315 91-96
• 19 Kipporah K, Carlton D, Bimbo L et al.. Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic lock solution.  Kidney Int. 2002;  61 1136-1142
• 20 Capdevilla J A, Segarra A, Planes A M, Ramirez-Arellano M, Panissa A, Piera L, Martnez-Vazquez J M. Successful treatment of haemodialysis catheter-related sepsis without catheter removal.  Nephrol Dial Transplant. 1993;  8 231-234
• 21 Kamal G D, Pfaller M A, Rempe L E et al.. Reduced intravascular catheter infections by antibiotic binding. A prospective, randomized controlled trial.  JAMA. 1991;  265 2365-2368
• 22 Dahlberg P J, Agger W A, Singer J R. Subclavian hemodialysis catheters infections: a prospective, randomized trial of an attachable silver-impregnated cuff for prevention of catheter-related infections.  Infect Control Hosp Epidemiol. 1996;  16 506-510
• 23 Gawaz M P, Dobos G, Spath M et al.. Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal failure.  J Am Soc Nephrol. 1994;  5 36-46
• 24 Eberst M E, Berkowitz L R. Hemostasis in renal disease: pathophysiology and management.  Am J Med. 1994;  96 168-179
• 25 Woods J D, Turenne M N, Strawgerman R L et al.. Vascular access survival among incident hemodialysis patients in the United States.  Am J Kidney Dis. 1997;  30 50-57
• 26 Goldwasser P, Michel M, Collier J. Prealbumin and lipoprotein (a) in hemodialysis: relationships with patient and vascular access survival.  Am J Kidney Dis. 1993;  22 215-225
• 27 Windus D W, Jendrisak M D, Delmez J A. Prosthetic fistula survival and complications in hemodialysis patients: effects of diabetes and age.  Am J Kidney Dis. 1992;  19 214-234
• 28 Casserly L F, Dember L M. Thrombosis in end-stage renal disease.  Semin Dial. 2003;  16 245-256
• 29 Brieger D B, Mak K H, Marchant K, Topol E J. Heparin-induced thrombocytopenia.  J Am Coll Cardiol. 1998;  31 1449-1459
• 30 Visentin G P, Ford S E, Scott J P, Aster R H. Antibodies from heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.  J Clin Invest. 1994;  93 81-88
• 31 Warkentin T E, Levine M N, Hirsh J et al.. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.  N Engl J Med. 1995;  332 1330-1335
• 32 Yamamoto S, Koide M, Matsuo M et al.. Heparin-induced thrombocytopenia in hemodialysis patients.  Am J Kidney Dis. 1996;  28 82-85
• 33 de Sancho M, Lema M G, Amiral J, Rand J. Frequency of antibodies directed against heparin-platelet factor 4 in patients exposed to heparin through chronic hemodialysis.  Thromb Haemost. 1996;  75 695-696
• 34 Greinacher A, Zinn S, Wizemann F, Birk U W. Heparin-induced antibodies as a risk factor for thromboembolism and haemorrage in patients undergoing chronic haemodialysis.  Lancet. 1996;  348 764
• 35 O'Shea S I, Lawson J H, Reddan D, Murphy M, Ortel T L. Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis.  J Vasc Surg. 2003;  38 541-548
• 36 Sheridan D, Carter C, Kelton J G. A diagnostic test for heparin-induced thrombocytopenia.  Blood. 1986;  67 27-30
• 37 Chong B H, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia.  Thromb Haemost. 1993;  69 344-350
• 38 Martinuzzo M E, Forastiero R R, Adamczuk Y, Pombo G, Carreras L O. Antiplatelet factor 4-heparin antibodies in patients with antiphospholipid antibodies.  Thromb Res. 1999;  95 271-279
• 39 Arepally G, Raynolds C, Tomaski A et al.. Comparison of PF4/Heparin ELISA assay with the 14C-serotonin assay in the diagnosis of heparin-induced thrombocytopenia.  Am J Clin Pathol. 1995;  104 648-654
• 40 Eichler P, Budde U, Haas S et al.. First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA.  Thromb Haemost. 1999;  81 625-629
• 41 Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific.  Thromb Haemost. 1992;  67 545-549
• 42 Warkentin T E, Elavathil L J, Hayward C PM, Johnston M A, Russerr J I, Kelton J G. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia.  Ann Intern Med. 1997;  127 804-813
• 43 Vanholder R, Camez A, Veys H, VanLoo A, Dhondt A M, Ringoir S. Pharmacokinetics of recombinant hirudin in hemodialyzed end stage renal failure patients.  Thromb Haemost. 1997;  77 650-655
• 44 Murray P T, Reddy B, Grossman E et al.. Pharmacokinetics (PK) and pharmacodynamics (PD) of argatroban anticoagulation in end-stage renal failure (ESRD) patients undergoing hemodialysis (HD).  J Am Soc Nephrol. 2003;  14 728A
• 45 Manns B J, Burgess E D, Parsons G, Schaffer J P, Hyndman M E, Scott-Douglas W S. Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients.  Kidney Int. 1999;  55 315-320
• 46 Mokrzycki M H, Jean-Jerome K, Rush H, Zdunek M P, Rosenberg S O. A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters.  Kidney Int. 2001;  59 1935-1942
• 47 Crowther M A, Catherine C M, Margetts P J. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial.  J Am Soc Nephrol. 2002;  13 2331-2337
• 48 Anderson C B, Codd J R, Graff R A et al.. Cardiac failure and upper extremity arteriovenous dialysis fistulas. Case reports and a review of the literature.  Arch Intern Med. 1976;  136 292-297
• 49 Vertes V, Cangiano J, Berman L. Hypertension in end stage renal disease.  N Engl J Med. 1969;  280 978-981
• 50 Horl M P, Horl W H. Hemodialysis-associated hypertension: pathophysiology and therapy.  Am J Kidney Dis. 2002;  39 227-244
• 51 Daugirdas J T. Pathophysiology of dialysis hypotension: an update.  Am J Kidney Dis. 2001;  38 S11-S17